尼氟灭酸抑制人脑胶质瘤U87细胞活力、迁移及侵袭  

Niflumic acid inhibits the proliferation,migration and invasion of glioma U87 cells

作　　者：崔万丽[1] 石雨淑雅 蔡欣池 田晶[1] CUI Wan-li;SHI Yu-shu-ya;CAI Xin-chi;TIAN Jing(Department of Physiology,Jilin Medical University,Jilin 132013,China;2016 Clinical Medicine Teaching Reform Class,Jilin Medical University,Jilin 132013,China)

机构地区：[1]吉林医药学院生理学教研室,吉林吉林132013 [2]吉林医药学院,吉林吉林132013

出　　处：《中国病理生理杂志》2020年第10期1887-1891,共5页Chinese Journal of Pathophysiology

基　　金：吉林省教育厅“十三五”科学技术研究项目(No.2016238);吉林省大学生创新创业项目(No.201613706029,No.201741)。

摘　　要：目的:观察尼氟灭酸(niflumic acid,NFA)对人胶质瘤U87细胞活力、迁移及侵袭的影响,并探讨其可能机制。方法:体外培养U87细胞,分为空白对照组和50、100及200μmol/L NFA组。MTT法检测各组U87细胞活力,实时无标记细胞分析(real-time cell analysis,RTCA)技术检测NFA对U87细胞迁移及侵袭的影响。结果:MTT检测结果显示,与空白对照组比较,NFA作用12 h后各组细胞活力显著增加(P<0.05或P<0.01),NFA作用24 h和48 h后,细胞活力显著降低(P<0.05或P<0.01),并呈现浓度依赖性。RTCA检测结果显示,与对照组比较,100和200μmol/L NFA组U87细胞迁移和侵袭能力均降低(P<0.05或P<0.01),200μmol/L NFA组U87细胞迁移和侵袭能力降低更加显著(P<0.01)。结论:NFA可以抑制胶质瘤U87细胞活力、迁移和侵袭。AIM:To investigate the effect of niflumic acid(NFA)on human glioma U87 cells and to clarify the potential mechanism.METHODS:The U87 cells were cultured in vitro and divided into blank control group,and 50,100 and 200μmol/L NFA groups.MTT assay was performed to determine the viability of cells in various groups.Mi⁃gration and invasion abilities were measured by real-time cell analysis(RTCA).RESULTS:The results of MTT assay showed that compared with blank control group,the viability of U87 cells was increased after treatment with NFA for 12 h(P<0.05 or P<0.01),while the viability was significantly decreased after treatment with NFA for 24 and 48 h(P<0.05 or P<0.01)in a concentration-dependent manner.The results of RTCA showed that compared with control group,the cell migration and invasion abilities were inhibited in 100 and 200μmol/L NFA groups(P<0.05 or P<0.01)and the inhibito⁃ry effects were more obvious in 200μmol/L NFA group(P<0.01).CONCLUSION:NFA inhibits the viability,migra⁃tion and invasion of human glioma U87 cells.

关 键 词：尼氟灭酸 胶质瘤 细胞活力 细胞迁移 细胞侵袭 

分 类 号：R739.41[医药卫生—肿瘤] R730.23[医药卫生—临床医学]